ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0046

Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion

Kenta Makabe1, Yasunori Omata1, Hiroyuki Okada1, Ryota Chijimatsu2, Asuka Terashima1, Fumiko Yano1, Sakae Tanaka1 and Taku Saito1, 1Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Okayama, Japan

Meeting: ACR Convergence 2022

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Gene Expression, Mouse Models, RA, pain, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Animal Models Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: In clinical trials for the treatment of rheumatoid arthritis, baricitinib was shown to significantly improve pain scores compared with anti-TNF inhibitors. This result suggests that baricitinib may regulate pain independently of arthritis improvement. Here, we aimed to reveal the mechanism underlying the regulation of pain by baricitinib, using the collagen antibody-induced arthritis (CAIA) mouse model.

Methods: We intragastrically administered baricitinib, celecoxib, or vehicle once per day to CAIA mice; we also administered vehicle to control mice without CAIA (Control group). We then analyzed the four groups. We evaluated the progression of arthritis by visual scoring, inflammatory pain by the grip strength test, and allodynia by the von Frey test. Dorsal root ganglion (DRG) and spinal cords were harvested on day 8 or 14 following induction of arthritis, to evaluate the expression of the pain-related molecules. We used RNA sequencing (RNAseq) and quantitative PCR to analyzed gene expression in the DRG. We used immunohistochemistry to examine activation of glial cells in the spinal cord.

Results: In CAIA mice with vehicle treatment (CAIA group), the progression of arthritis and decrease in grip strength were severe around day 8 and gradually attenuated thereafter, while allodynia peaked around day 14 and was sustained. Arthritis and grip strength were equivalently improved in the baricitinib and celecoxib groups compared with the CAIA group. However, allodynia was markedly suppressed to a level similar to that seen in the Control group by baricitinib treatment but not by celecoxib treatment. RNAseq showed that the expression of genes related to inflammation and the immune response increased in the DRG of the CAIA group at day 8, compared with the Control group. The upregulated genes were decreased in the baricitinib group. Notably, the increased expression of IL-6-JAK-STAT3 pathway-related genes by CAIA was attenuated by baricitinib treatment. Expression of Socs3, a representative downstream gene of the JAK/STAT pathway, was significantly suppressed in the baricitinib group. The activation of glial cells, particularly astrocytes, was significantly more inhibited in the spinal cords of the baricitinib group than in those of the celecoxib group at day 14.

Conclusion: Only baricitinib treatment suppressed allodynia in CAIA mice, while both baricitinib and celecoxib improved arthritis and inflammatory pain. Baricitinib also suppressed gene expression related to the inflammation and immune responses in the DRG of CAIA mice and the subsequent activation of astrocytes in the spinal cord. Baricitinib may contribute to the amelioration of residual allodynia in rheumatoid arthritis via modulating the IL6-JAK-STAT3 pathway in the DRG, as well as that of arthritis itself.

Supporting image 1

Figure. Evaluation of arthritis in CAIA mice.
n = 4, two-way ANOVA followed by Tukey’s multiple comparisons test. Values are the means ± SEM
*p<0.05, ** p<0.01, *** p<0.001 (CAIA + Baricitinib vs CAIA)


Disclosures: K. Makabe, None; Y. Omata, None; H. Okada, None; R. Chijimatsu, None; A. Terashima, None; F. Yano, None; S. Tanaka, None; T. Saito, None.

To cite this abstract in AMA style:

Makabe K, Omata Y, Okada H, Chijimatsu R, Terashima A, Yano F, Tanaka S, Saito T. Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/baricitinib-ameliorates-residual-neuropathic-pain-in-collagen-antibody-induced-arthritis-mice-by-suppressing-inflammation-of-the-dorsal-root-ganglion/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baricitinib-ameliorates-residual-neuropathic-pain-in-collagen-antibody-induced-arthritis-mice-by-suppressing-inflammation-of-the-dorsal-root-ganglion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology